### Introduction

OSAS is an underdiagnosed chronic disease characterised by recurrent episodes of apnoeas and hypopnoeas due to complete or partial occlusion of the upper airway during sleep \(^1\). A recent epidemiological study in adults showed that 49.7% of men and 23.4% of women have moderate to severe OSAS defined as an apnoea-hypopnoea index (AHI) ≥ 15/hour \(^2\). Untreated patients are at significantly increased risk of developing cardiovascular \(^3\)\(^4\), metabolic \(^5\)\(^7\) and neurocognitive diseases \(^8\), as well as motor vehicle (MVAs) \(^9\)\(^10\) and/or work accidents \(^10\)\(^11\). Concern that OSAS is a health issue of great relevance with having an adverse impact on the quality \(^12\) and life expectancy \(^13\) and on economic systems is growing \(^14\)\(^15\). Furthermore,
in Europe, it is expected that there will be an exponential increase in the number of diagnosed OSAS subjects. Two main reasons account for this: 1) the increase in OSAS prevalence in the last decades is associated with increasing prevalence and severity of obesity, the first risk factor for OSAS; 2) in EU countries, according to the Commission directive 2014/85/EU, testing for OSAS is mandatory before granting or renewing a driver’s license. Applicants or drivers with moderate or severe OSAS under treatment shall be subjected to a periodic medical review, with intervals not exceeding three years for drivers of group 1 and one year for drivers of group 2. The huge expected increase in number of diagnosis of OSAS is a challenge for health systems, leading to the need to manage OSAS and related problems by simplified tests and developing new models based on cost-effectiveness. Although a simplified and cost-effectiveness approach may help to meet the increase in number of OSAS diagnoses, it must be pointed out that the directive requires a mandatory cut-off (AHI ≥ 15 with excessive daytime sleepiness) for OSAS testing. It is therefore imperative, for clinical and regulatory reasons, to make a proper diagnosis and offer appropriate treatment. Objective sleep studies for OSAS may be of two types: Sleep Laboratory Polysomnography (PSG) and Home Sleep Testing (HST), the former is considered the diagnostic “gold standard” although highly time consuming and expensive. As a result, suspected OSAS patients may be left waiting for months before being diagnosed and able to initiate treatment. American Academy Sleep Medicine (AASM) and the American Thoracic Society (ATS) recommend the management of OSAS by HST in pre-test subjects with high OSAS suspicion without notorious morbidity or suspicion of neurological disorders, as stated in their guidelines for the use of portable monitors. In addition, HST is considered a cost-effective alternative for OSAS diagnosis in selected patients. Our aim is to review models based on cost-effectiveness to meet the increasing request for OSAS diagnosis and treatment. In 2016, the Italian Ministry of Health produced a document aimed to prevent and assess the clinical pathways for OSAS patients by proposing the creation of a dedicated interdisciplinary network of care.

The care of OSAS

International statements on care of OSAS are: a) diagnosis should be confirmed by objective testing; b) therapeutic choice comes from a multidisciplinary assessment; c) all patients should undergo long term follow-up to monitor treatment effectiveness and adherence to therapy. Developed in the early 1980’s, CPAP has become established as the treatment of choice for OSAS. It is effective as a treatment of OSAS symptoms and among all available treatments, it has the strongest evidence for a beneficial cardiovascular effect. It has also been proven to be effective in reducing MVAs and to improve quality and expectancy of life. The full-night attended sleep laboratory PSG is the gold standard for the OSAS diagnosis and for CPAP titration aimed to determine the optimal positive airway pressure. More recent studies have shown that alternatives OSAS therapies, like upper airway surgery and even oral appliances, are as effective as CPAP in mild and moderate OSAS. Indeed, although CPAP is established as a highly efficacious treatment for OSAS, its effectiveness has been limited by poor adherence. Users may experience nasal discomfort, congestion, mask leak and claustrophobia which lead to variable levels of long term compliance ranging from 46% to 85% depending on the criteria used to define it. It has been described a fairly linear dose response relationship such that the greater the CPAP usage, the greater the improvement in sleepiness, quality of life (QoL) and blood pressure outcomes. As a result, there has been much research on methods to optimise CPAP adherence. Interventions that have been conducted include the verbal-visual instruction by health professionals, the application of the nasal and oral-nasal masks as well as the importance of the disease and its health effects, with standardised audiovisual presentations and practical demonstrations on performing standards treatments at home. Up to now, gold standard training programs in literature have steadily improved the adherence to CPAP treatment. Many of these clinical trials with double arms (control and study) have given controversial results. These latter studies were also criticised due to the higher level of education of the control arm compared to the study arm vs. normal routine care. Consequently, results on the adherence in the study arm appeared worse. However, the majority of the experts still recommend to all patients that starting CPAP requires a high level of intensive instruction. Any educational approach, however, necessary to achieve the best possible adherence to long-term treatment, is time and money consuming.

Sleep laboratory polysomnography vs home sleep testing

HST is validated for diagnosis of OSAS as well as for titration of positive airway pressure (PAP) and oral appliances (OA) devices, and auto titrating PAP (APAP) devices may be used in an unattended way to determine the therapeutic continuous PAP value. Some studies have compared the cost-utility of different diagnostic/therapeutic strategies for the diagnosis of OSAS. Pietzsch et al. have assessed the cost-benefit ratio by comparing the three most used diagnostic/therapeutic strategies: a) full-night attended sleep laboratory PSG with manual CPAP titration; b) split-night PSG along with manual CPAP titration; c) HST with subsequent treatment.
with auto-titrating PAP (APAP). In this study, for a patient with moderate-to-severe OSAS, CPAP therapy has an incremental cost-effectiveness ratio (ICER) of $15,915 per QALY (Quality Adjusted Life Years) gained for the lifetime horizon. Over the lifetime horizon in a population with 50% prevalence of OSAS, full-night polysomnography in conjunction with CPAP therapy is the most economically efficient strategy at any willingness-to-pay greater than $17,131 per QALY gained, because it dominates all other strategies in comparative analysis.

In a more recent study, 191 suspected OSAS patients were studied in advance using a pre-clinical test. More than half (56.5%) were suspected of having OSAS. Without involvement of a sleep medicine specialist, obstructive sleep apnoea was not identified in only 5.8% of the sample. The probability to obtain an accurate diagnosis using pre-clinical tests seems not to be influenced by the presence/absence of a specialist sleep physician in accordance with the severity of the disease. The authors concluded that severe OSAS can be reliably identified with HST in a non-referred sample, irrespective of the pretest probability of the disease. Although these studies support, even from an economic point of view, the widespread use of the HST for OSAS diagnosis, it should be pointed out that, as reported by the American Academy of Sleep Medicine, HST may underestimate the seriousness of the hypopnoeic events compared to a full night attended sleep laboratory PSG. This remark is not only important from a clinical and therapeutic point of view for the individual patient, but also for regulatory reasons. Indeed, as indicated by the Directive, an underestimation of the seriousness and number of apnoeas and hypopnoeas with an AHI < 15, can result in a lack of diagnosis for an OSAS subject at risk for MVAs if the driver is not in treatment for OSAS. The AASM also remarks that HST is not indicated in case of suspected sleep related breathing disorders other than OSAS, major comorbid conditions including moderate to severe pulmonary disease, neuromuscular disease, congestive heart failure and sleep disorder. These are almost all high-prevalence diseases. Furthermore, it must pointed out some relevant limitations about HST when used in a long-term management strategy. These include: a) the need to review/reevaluate the raw data that come automatically without performing a manual analysis of the nocturnal polygraphic tracings; b) uncertainties about the long-term use of this outpatient strategy regarding the overall cost-effectiveness compared to a hospital diagnostic plan that is based on supervised polysomnography at 1st level.

Of note, these trials for OSAS diagnosis in primary care excluded patients with comorbidities, including chronic obstructive pulmonary disease or congestive heart failure. For these latter, the concordance between HST and PSG is inadequate, due to either poor oximetry and flow recordings in a significant number of patients.

A randomised, controlled, non-inferiority study involved patients with OSAS who were treated with HST and compared with a specialist model (Sleep Laboratory Polysomnography). Among patients with OSAS, treatment under HST did not result in worse sleepiness scores and general quality of life measures, suggesting that the two treatment models may be comparable. Andreu et al. evaluated the efficacy of a home-based programme on clinical response, (CPAP) compliance and cost in a population of high pre-test probability of suffering (OSAS). Patients were randomised into the following three groups with no between-group differences. Group A: home respiratory polygraphy (RP) and home follow-up; Group B: hospital PSG and hospital follow-up; and Group C: home RP and hospital follow-up. Evaluation during 6 months included Epworth Sleepiness Scale (ESS), Functional Outcomes Sleep Questionnaire (FOSQ) and daily activity and symptom questionnaires. Compliance was assessed by memory cards (group A) and using an hourly counter (groups B and C). The randomised prospective study in 65 patients demonstrated that patients with a high initial probability of having OSAS can be diagnosed and treated in a home setting, with a high level of CPAP compliance and lower cost than either a hospital-based approach or home RP/hospital follow-up.

Health-care providers and models of care to manage OSAS

Different approaches and strategies have been proposed to counteract the increasing demand for access to diagnosis and therapy for OSAS. The US created a home care model, based on HST and refundable by the insurance agencies, that deals with both diagnosis and therapeutic care of OSAS patients. This services company, called the Affordable Care Act (ACA) aims to provide high quality healthcare to OSAS patients. The ACA is gearing up towards a diagnostic model that focuses on the doctor-patient relationship. In this home care model, the company puts a network of healthcare services at the centre of this relationship, where primary care is subsequently and rapidly integrated after diagnosis. Basically, once diagnosis and the treatment are determined, the Agency rapidly provides home care technical support. Home care diagnosis and treatment is performed by health care professionals along with a consultation with a sleep specialist. This approach reduces the costs of medical staff and simplifies the delivery steps in providing therapeutic equipment at home.

Telemedicine is a remote communication system of Information Technology IT/medical data that is used to save time and reduce costs for managing a home care service for chronic diseases. A number of clinical studies have been carried out to evaluate the effectiveness of telemedicine interventions on adherence to CPAP treatment.
The IT reports were transmitted and received from patient CPAP treatment home units to the reference provider centre wirelessly, and data from the study were collected and processed (Home ↔ Provider). The data collected were: a) loss of pressure in the mask during sleep to CPAP treatment; b) residual AHI during CPAP treatment; c) number of hours of CPAP use. Errors in performing the treatment were easily detected from the technician, who was able to call the patients the next morning through the central Provider and resolve problems about the low efficiency of treatment. In a multicentre randomised controlled trial, telemedicine was used to study the economic and clinical impact as well the improvement of the QoL with CPAP treatment compared to traditional follow-up with face-to-face doctor-patient controls. The 139 enrolled patients were sufficiently confident with the IT world. The quality of sleep, side effects of treatment with CPAP and QoL were evaluated at 1, 3 and 6 months. It was observed that a strategy based on telemedicine resulted in reduction of transport service and productivity costs.

PREDICT, a multicentre randomised controlled study used the telemedicine to assess the clinical and economic aspects of CPAP treatment in OSAS patients older than 65 years. It was found that CPAP treatment reduced subjective and objective sleepiness to that observed in younger patients. Secondary goals were to determine CPAP clinical efficacy, cost-effectiveness ratio and real usefulness of treatment (model-based cost-effectiveness analysis) compared to alternative treatments with APAP/Bilevel/C FLEX (BSC). The QoL at 12 months of treatment was measured by the European Quality of Life-5 Dimensions (EQ-5D). In elderly patients with OSAS, CPAP treatment reduced somnolence more significantly compared to treatment with APAP/Bi-Level/C FLEX (BSC) over a period of 12 months, improving the EQ-5D. Although IT telemonitoring systems saved operating costs and managed several patients simultaneously (at least 100), by using a single provider they hinted at possible medico-legal disputes. First of all, there is no international standard of care for telemedicine. Standards of care exist only for services for the individual, but there are still not many e-Health practices. Medico-legal issues are: a) respect for personal privacy, b) inaccuracies of self-reporting of patients in data recording, c) the resolution limits of data to be recorded and consequent delays due to failure/delayed treatment after recording of data, d) failure of systems that do not work correctly.

In the US, there is a national society in telemedicine called TelaDoc that features a American National Committee to guarantee certification of electronic systems used in tel-

---

**Fig. 1.** Model of OSAS management resulting from cost-effectiveness strategies.
OSAS ambulatory management

emedicine, along with the production of evidence-based clinical practice guidelines for registering data quality 60. There are emerging results in the literature that support the role of non-medical health professionals who are expert in sleep study, such as nurses, caregivers and IT/health care, who are able to manage home care OSAS in a cost-effective way. We still need more long-term prospective studies that can evaluate the cost-effectiveness ratio, including direct and indirect costs of hospital management models versus models that take into account new, qualified non-medical personnel care.

Another randomised, prospective, controlled study included OSAS patients who underwent CPAP treatment and HST during follow-up. The primary outcome was CPAP compliance at 6 months. Secondary outcomes were ESS score, EuroQoL, patient satisfaction, body mass index (BMI), blood pressure and cost-effectiveness. For patients with OSAS, the treatment provided did not result in worse CPAP compliance compared with a specialist model (Sleep Center Polysomnography) and was shown to be a cost-effective alternative 61.

Conclusions

The huge expected increase in the prevalence and incidence of OSAS is a challenge for healthcare systems. The model of OSAS management resulting from cost-effectiveness strategies is shown in Figure 1. Healthcare systems must ensure rapid access to diagnosis and treatment for each individual with suspected OSAS and avoid exposure to the risk of MVAs and work accidents for both OSAS subjects and others involved in accidents caused by OSAS subjects. HST, health-care providers and the proposed model aimed to manage OSAS are a possible effective response to counteract the increasing demand for access to diagnosis and therapy for OSAS. It takes priority to involve non-medical healthcare professionals and create training courses for all health workers on the management of OSAS and OSAS-related problems. Whatever the strategy chosen and/or organisational model adopted for managing OSAS, it cannot and should not take into account only cost-effectiveness. Long-term prospective studies aimed at evaluating the cost-effectiveness ratio, accuracy of diagnosis and outcomes of OSAS treatment of hospital management models versus home care models are needed.

References


27 George CF. Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. Thorax 2001;56:508-12.


49 Glied S, Solís-Román C, Parikh S. How the ACA’s health insurance expansions have affected out-of-pocket cost-sharing and spending on premiums. Issue Brief (Commonw Fund) 2016;28:1-16.


59 Uscher-Pines L, Mehrotra A. Analysis of Teladoc use seems to indicate expanded access to care for patients without prior connection to a provider. Health Aff (Millwood) 2014;33:258-64.


Received: November 30, 2016 - Accepted: March 11, 2017